|
1.
|
|
16 p, 3.4 MB |
CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors
/
Dragon, Anna Christina (Hannover Medical School) ;
Beermann, Luca Marie (Hannover Medical School) ;
Umland, Melina (Hannover Medical School) ;
Bonifacius, Agnes (Hannover Medical School) ;
Malinconico, Chiara (Hannover Medical School) ;
Ruhl, Louisa (Hannover Medical School) ;
Kehler, Patrik (Glycotope GmbH) ;
Gellert, Johanna (Glycotope GmbH) ;
Weiß, Lisa (Glycotope GmbH) ;
Mayer-Hain, Sarah (Glycotope GmbH) ;
Zimmermann, Katharina (Hannover Medical School) ;
Riese, Sebastian (Hannover Medical School) ;
Thol, F. (Department of Hematology. Hannover Medical School) ;
Beutel, Gernot (Hannover Medical School) ;
Maecker-Kolhoff, B. (Department of Pediatric Hematology and Oncology. Hannover Medical School) ;
Yamamoto, Felicitas (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blasczyk, Rainer (Hannover Medical School) ;
Schambach, Axel (Hannover Medical School) ;
Hust, Michael (Department of Medical Biotechnology. Technical University of Braunschweig) ;
Hudecek, Michael (Department of Internal Medicine II. University Hospital of Würzburg) ;
Eiz-Vesper, Britta (Hannover Medical School) ;
Universitat Autònoma de Barcelona
Introduction: Chimeric antigen receptor-engineered T cells (CAR-Ts) are investigated in various clinical trials for the treatment of cancer entities beyond hematologic malignancies. A major hurdle is the identification of a target antigen with high expression on the tumor but no expression on healthy cells, since "on-target/off-tumor" cytotoxicity is usually intolerable. [...]
2023 -  10.3389/fimmu.2023.1219165
Frontiers in immunology, Vol. 14 (2023) , p. 1219165
|
|
|
2.
|
|
13 p, 3.0 MB |
Defining the optimal sequence for the systemic treatment of metastatic breast cancer
/
Albanell Mestres, Joan (Hospital del Mar (Barcelona, Catalunya)) ;
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez, Leticia C. (Complejo Hospitalario Universitario de A Coruña) ;
López-Muñiz, José Ignacio Chacón (Hospital Virgen de la Salud (Toledo)) ;
Ciruelos, Eva (Hospital 12 de Octubre (Madrid)) ;
de Juan Ferre, Ana (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
del Barco Berrón, S. (Institut Català d'Oncologia) ;
Pérez, Y.F. (Hospital Universitario Central de Asturias) ;
Mata, J.G. (Hospital Santa María Nai en Ourense) ;
Palomo, A.G. (Complejo Asistencial de León) ;
Gregori, J.G. (Fundació Institut Valencià d'Oncologia) ;
Pardo, P.G. (Hospital Universitari Vall d'Hebron) ;
Mañas, J.J.I. (Complejo Hospitalario de Navarra) ;
Hernández, A.L. (Hospital Clínic Universitari (València)) ;
de Dueñas, E.M. (Consorci Hospitalari Provincial de Castelló) ;
Jáñez, N.M. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Murillo, S.M. (Hospital Universitari Arnau de Vilanova) ;
Bofill, J.S. (Hospital Universitario Nuestra Señora de Valme) ;
Auñón, P.Z. (Hospital Universitario La Paz (Madrid)) ;
Sanchez-Rovira, P. (Complejo Hospitalario de Jaén) ;
Universitat Autònoma de Barcelona
Metastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing number of therapeutic options makes it difficult to determine the best choice in each particular situation. [...]
2017 - 10.1007/s12094-016-1520-2
Clinical & Translational Oncology, Vol. 19 Núm. 2 (january 2017) , p. 149-161
|
|
|
3.
|
|
8 p, 547.4 KB |
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
/
Du, Yong (The Royal Marsden NHS Foundation Trust) ;
Carrió, Ignasi (Institut d'Investigació Biomèdica Sant Pau) ;
De Vincentis, Giuseppe (Policlinico Umberto I University Hospital Rome) ;
Fanti, Stefano (University Hospital Bologna) ;
Ilhan, Harun (Ludwig-Maximilians-University Hospital) ;
Mommsen, Caroline (Praxis für diagnostische und therapeutische Nuklearmedizin Berlin) ;
Nitzsche, Egbert (Canton Hospital Aarau) ;
Sundram, Francis (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Vogel, Wouter (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Oyen, Wim (The Institute of Cancer Research) ;
Lewington, Val (Guy's and St Thomas' NHS Foundation Trust) ;
Universitat Autònoma de Barcelona
Radium Ra 223 dichloride (radium-223, Xofigo®) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach. [...]
2017 - 10.1007/s00259-017-3756-7
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 44 Núm. 10 (january 2017) , p. 1671-1678
|
|
|
4.
|
|
21 p, 9.8 MB |
Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors
/
Mira, Alessia (Candiolo Cancer Institute) ;
Morello, Virginia (University of Torino Medical School) ;
Céspedes, María Virtudes (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Perera, Timothy (OCTIMET Oncology Ltd) ;
Comoglio, Paolo M. (Candiolo Cancer Institute) ;
Mangues, Ramon 1957- (Institut d'Investigació Biomèdica Sant Pau) ;
Michieli, Paolo (University of Torino Medical School) ;
Universitat Autònoma de Barcelona
The role of paracrine Hepatocyte Growth Factor (HGF) in the resistance to angiogenesis inhibitors (AIs) is hidden in xenograft models because mouse HGF fails to fully activate human MET. To uncover it, we compared the efficacy of AIs in wild-type and human HGF knock-in SCID mice bearing orthotopic human colorectal tumors. [...]
2017 - 10.18632/oncotarget.16942
Oncotarget, Vol. 8 Núm. 24 (2017) , p. 38193-38213
|
|
|
5.
|
|
9 p, 9.3 MB |
Polybenzoxazines as new photothermal therapy agents
/
Reyes-Mateo, Kevin (Universitat Autònoma de Barcelona. Departament de Química) ;
Careta, Oriol (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Hernando Campos, Jordi (Universitat Autònoma de Barcelona. Departament de Química) ;
Nogués, C. (Carme) (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Sebastián, Rosa María (Universitat Autònoma de Barcelona. Departament de Química)
To make photothermal therapy an attractive alternative to conventional cancer treatments, the development of novel photothermal agents with enhanced properties is demanded. To tackle this challenge, herein we explored the use of polybenzoxazines, a well-known class of phenolic resins. [...]
2023 - 10.1016/j.eurpolymj.2023.112531
European Polymer Journal, Vol. 201 (December 2023) , art. 112531
|
|
|
6.
|
|
11 p, 1.5 MB |
Intermittent androgen deprivation therapy : Recommendations to improve the management of patients with prostate cancer following the GRADE approach
/
Bonfill, X. (Xavier) (Institut d'Investigació Biomèdica Sant Pau) ;
Arevalo-Rodriguez, Ingrid (Hospital Ramon y Cajal (IRYCIS)) ;
Martínez García, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Quintana Ruiz, Maria Jesús (Institut d'Investigació Biomèdica Sant Pau) ;
Buitrago-Garcia, Diana (Universidad Tecnológica Equinoccial) ;
Lobos Urbina, D. (Pontificia Universidad Católica de Chile) ;
Cordero, José Antonio (Universitat Ramon Llull) ;
Universitat Autònoma de Barcelona
The purpose of this study was to provide evidence-based recommendations of intermittent androgen deprivation therapy (IADT) compared with continuous androgen deprivation therapy (CADT) for men with prostate cancer (PCA). [...]
2018 - 10.2147/CMAR.S164856
Cancer Management and Research, Vol. 10 (2018) , p. 2357-2367
|
|
|
7.
|
|
12 p, 144.7 KB |
Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
/
Puente, J. (Medical Oncology Department. Hospital Clínico San Carlos. Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC). CIBERONC) ;
Anido, Urbano (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Climent, M.Á. (Instituto Valenciano de Oncología (IVO)) ;
Gonzalez-Billalabeitia, E. (Universidad Católica San Antonio de Murcia-UCAM) ;
Lainez, N. (Complejo Hospitalario de Navarra) ;
Lambea, Julio (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Mendez-Vidal, M.J. (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Montesa, Álvaro (Hospital Regional Universitario de Málaga) ;
Rodriguez, A. (Hospital Universitario de León) ;
Zambrana, C. (Hospital Universitario Infanta Sofía (San Sebastián de los Reyes)) ;
González-del-Alba, A. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Universitat Autònoma de Barcelona
Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT. [...]
2020 - 10.1177/1758835920920067
Therapeutic Advances in Medical Oncology, Vol. 12 (2020)
|
|
|
8.
|
|
13 p, 423.1 KB |
Pharmacological cancer treatment and venous thromboembolism risk
/
Muñoz Martín, A.J. (Hospital General Universitario Gregorio Marañón) ;
Ramírez, S.P. (Hospital General Universitario Gregorio Marañón) ;
Morán, L.O. (Hospital General Universitario Gregorio Marañón) ;
Zamorano, M.R. (Universidad Complutense de Madrid) ;
Benéitez, M.C.V. (Universidad Complutense de Madrid) ;
Salcedo, I.A. (Hospital General Universitario Gregorio Marañón) ;
Escobar, I.G. (Hospital General Universitario de Ciudad Real) ;
Soria Fernández, José Manuel (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Risk factors for cancer-associated thrombosis are commonly divided into three categories: patient-, cancer-, and treatment-related factors. Currently, different types of drugs are used in cancer treatment. [...]
2020 - 10.1093/EURHEARTJ/SUAA004
European heart journal supplements, Vol. 22 (2020) , p. C2-C14
|
|
|
9.
|
|
9 p, 267.6 KB |
VITAL phase 2 study : Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)
/
Feliu, Jaime (Hospital Universitario La Paz (Madrid)) ;
Garcia-Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ;
Capdevila, J (Vall d'Hebron Institut d'Oncologia) ;
Guasch, Inmaculada (Hospital Althaia Assistencial de Manresa) ;
Alonso-Orduña, Vícente (Hospital Universitario Miguel Servet (Saragossa)) ;
López-López, Carlos A. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Castañón, Carmen (Hospital Virgen Blanca) ;
Sevilla, Isabel Ñíguez (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Cerezo, Laura (Hospital Universitario de la Princesa (Madrid)) ;
Conill, Carlos (Universitat de Barcelona) ;
Quintana Ángel, Begoña (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sánchez, María E. (Hospital Universitario La Paz (Madrid)) ;
Ghanem, Ismael (Hospital Universitario La Paz (Madrid)) ;
Martín-Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Lopez-Gomez, Miriam (Hospital Universitario Infanta Sofía (San Sebastián de los Reyes)) ;
León, Ana Isabel (Hospital Universitario Fundacion Jimenez Diaz) ;
Caro, Monica (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fernandez, Teresa López (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Maurel, Joan (Universitat de Barcelona) ;
Universitat Autònoma de Barcelona
VITAL, a phase II single-arm study, aimed to evaluate efficacy and safety of panitumumab addition to 5-fluorouracil (5-FU), mitomycin-C (MMC) and radiotherapy (RT) in patients with localized squamous cell carcinoma of the anal canal (SCCAC). [...]
2020 - 10.1002/cam4.2722
Cancer Medicine, Vol. 9 Núm. 3 (january 2020) , p. 1008-1016
|
|
|
10.
|
|
13 p, 792.3 KB |
SEOM clinical guideline thyroid cancer (2019)
/
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Medina, J. (Hospital Virgen de la Salud (Toledo)) ;
Sánchez, J.C. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Viúdez, A. (Complejo Hospitalario de Navarra) ;
Grande, E. (MD Anderson Cancer Center) ;
Porras, I. (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Trigo, J. (Hospital Universitario Regional Virgen de la Victoria) ;
Iglesias, L. (Hospital 12 de Octubre (Madrid)) ;
Capdevila, J. (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Thyroid carcinoma is the most frequent endocrine malignancy and accounts for around 3% of global cancer incidence. Different histologies and clinical scenarios make necessary a multidisciplinary approach that includes new diagnostic methods and surgical, radiopharmaceutical and systemic therapies. [...]
2020 - 10.1007/s12094-019-02284-8
Clinical & Translational Oncology, Vol. 22 Núm. 2 (january 2020) , p. 223-235
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
